3SBio Inc represents a commitment to innovation, integrity, and excellence in the biopharmaceutical industry. The company values putting patients first and developing high-quality therapeutic solutions. With a focus on research and development, 3SBio Inc is dedicated to discovering, developing, and commercializing innovative biopharmaceutical products. The company's corporate philosophy centers around offering effective and affordable treatments to improve patients' lives. By staying true to their core values, 3SBio Inc aims to make a positive impact on healthcare and contribute to the well-being of individuals worldwide.

3SBio Inc is primarily present in China and the United States.

3SBio Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) on the Hong Kong Stock Exchange in 2015, marking a major milestone in its history. Furthermore, 3SBio Inc has seen remarkable growth and success in the biopharmaceutical industry, particularly in the development and commercialization of innovative medicines. They have obtained regulatory approvals for various products, expanded their product portfolio, and established strategic partnerships to enhance their market presence. The company's dedication to research and development has also resulted in numerous scientific achievements and breakthroughs. Overall, 3SBio Inc has demonstrated consistent progress and remains a leading player in the biopharmaceutical sector.

3SBio Inc is a leading biotechnology company specializing in the research, development, and manufacturing of innovative biopharmaceutical products. Founded in 1993, the company has a rich history in the biotech industry. With its headquarters in China, 3SBio Inc has expanded globally and gained recognition for its expertise in therapeutic areas including nephrology, oncology, and immunology. The company is committed to improving patient outcomes through the development of high-quality, life-saving medications. 3SBio Inc has established itself as a trusted name in the biopharmaceutical sector, delivering innovative solutions to address unmet medical needs and improve the quality of life for patients worldwide.

The main competitors of 3SBio Inc in the market include companies such as Johnson & Johnson, Pfizer Inc, Novartis International AG, Amgen Inc, and Roche Holding AG.

3SBio Inc is primarily active in the biotechnology and pharmaceutical industries.

3SBio Inc operates as a leading biotechnology company. The business model of 3SBio Inc revolves around the research, development, manufacturing, and commercialization of biopharmaceutical products. The company focuses on developing innovative therapies to address unmet medical needs, particularly in the fields of oncology, nephrology, and autoimmune diseases. By leveraging their expertise in biologics and in-house manufacturing capabilities, 3SBio Inc aims to deliver high-quality and affordable medicines to patients worldwide. With a commitment to advancing healthcare, 3SBio Inc continues to invest in R&D efforts and strategic partnerships, aiming to improve patient outcomes and enhance their market presence.

مُعامل القيمة السوقية إلى الأرباح لـ 3SBio هو ٦٫٦٧.

مُعامِل القيمة إلى المبيعات 3SBio هو ١٫٤٦.

نقاط جودة AlleAktien لـ 3SBio هي 8/10.

المتوقعة 3SBio الإيرادات هي ٨٫٩٢ مليارات CNY.

صافي الربح المتوقعة 3SBio هو ١٫٩٥ مليارات CNY.

The Chinese company 3SBio Inc is a leading company in the biopharmaceutical industry, specializing in the development, manufacturing, and marketing of biological drugs. 3SBio focuses on the areas of oncology, immunology, nephrology, and infectious diseases. The main products of 3SBio include biosimilars of innovative drugs such as rituximab, enoxaparin, adalimumab, darbepoetin alfa, pegaspargase, and etanercept. Biosimilars are biologically manufactured drugs that have similar active ingredients as original biologics and thus provide a more cost-effective alternative. 3SBio has the largest market share for biosimilars in China and continually expands its portfolio. In addition to biosimilars, 3SBio also offers innovative biological drugs. One example is Tpiao, a recombinant human thrombopoietin receptor agonist. It is used to treat thrombocytopenia in patients with hepatitis B or hepatitis C infections. Another important area for 3SBio is nephrology. The company has various products in its portfolio that are used to treat kidney diseases. These include, for example, the erythropoiesis-stimulating agent (ESA) ferumoxytol, which is used to treat iron deficiency anemia in chronic kidney disease, as well as binodenoson, an adenosine receptor agonist used for diagnostic imaging of kidney diseases. The business model of 3SBio Inc is based on the acquisition of promising technologies, its own research and development work, and the manufacturing and marketing of biological drugs. The company works closely with regulatory authorities and health organizations to achieve fast market approval for its products. An important aspect is also international distribution. 3SBio strategically enters growth markets in Asia, especially in China, and expands into other parts of the world. Through partnerships with other companies and the acquisition of firms in the biopharmaceutical industry, 3SBio continuously expands its value chain and its portfolio. Overall, 3SBio pursues a diversified business model based on the utilization of synergies in the areas of research, development, manufacturing, and marketing of biological drugs. By utilizing biosimilars and innovative active ingredients, the company has achieved high competitiveness and is on a path of expansion.

يوزع 3SBio أرباحًا قدرها ٠٫٢٠ CNY من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ 3SBio في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـ3SBio هو KYG8875G1029.

رمز WKN لـ 3SBio هو A14T7Q.

الرمز المُختصر لـ 3SBio هو 1530.HK.

خلال آخر 12 شهراً، دفعت 3SBio توزيعات أرباح بقيمة ٠٫١٠ CNY . وهذا يعادل عائد توزيعات أرباح يقارب ١٫٨٨ %. ومن المتوقع أن تدفع 3SBio خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ٠٫١١ CNY.

نسبة توزيعات الأرباح الحالية لـ 3SBio هي ١٫٨٨ %.

3SBio يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر يوليو, يوليو, يوليو, أغسطس.

3SBio دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة ٠٫١١ CNY. وهذا يعادل عائد توزيعات أرباح قدره ٢٫٠٩ %.

3SBio يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة ٠٫٢٥ CNY من 3SBio المُعلن عنها في ٥‏/٨‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ٢٢‏/٧‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ٥‏/٨‏/٢٠٢٤.

في العام 2023، وزعت 3SBio ٠٫٢ CNY كأرباح أسهم.

يتم توزيع أرباح 3SBio بالعملة CNY.